Cardiotoxicity in people undergoing cancer treatment - the role of the oncology nurse

Abstract

Cardiotoxicity is a significant complication of cancer treatment, and this review describes the cardiovascular risks associated with various therapies and emphasizes the crucial role of oncology nurses in managing these risks. Many cancer treatments, including cytotoxic therapies, radiation, targeted therapies, and immune-modulatory drugs, have been shown to increase the likelihood of cardiovascular toxicity, leading to conditions such as acute coronary syndrome, heart failure, and atrial fibrillation. Guidelines are now available to reduce treatment-related cardiovascular toxicity (CTR-CVT) and stress the importance of cardiovascular assessments before, during, and after cancer treatment. Oncology nurses are pivotal in performing these assessments and collaborating within multidisciplinary teams, including cardiologists, to ensure optimal care. As more patients successfully complete cancer treatment, it becomes essential to integrate cardiovascular risk evaluation, education, and medication into routine oncology care. The evolving field of oncology nursing, particularly with the rise of emerging therapies and aging populations, requires further education on early detection and management of cardiotoxicity to enhance patient outcomes.